mer. mai 19, 2010 4:11 pm
Combination Therapy Targets Stubborn Leukemia Stem Cells
ScienceDaily (May 17, 2010)
'New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the new therapeutic strategy effectively targets notoriously intractable leukemia stem cells that often escape standard treatment and are a main factor in disease relapse.
....
Dr. Bhatia and colleagues were interested in examining whether histone deacetylase inhibitors (HDACi) that have shown some promise as a treatment for several other cancers, might be effective at eliminating CML stem cells. HDACi were of interest because they not only target rapidly dividing cancer cells but also have been shown to eliminate non-proliferating cancer cells. The researchers found that treatment with a combination of HDACi and IM effectively reduced CML cells that were resistant to IM alone. Further, a combination of HDACi and IM markedly diminished leukemia stem cells in a mouse model of CML
.....
The researchers include Bin Zhang, City of Hope National Medical Center, Duarte, CA; Adam C. Strauss, City of Hope National Medical Center, Duarte, CA; Su Chu, City of Hope National Medical Center, Duarte, CA; Min Li, City of Hope National Medical Center, Duarte, CA; Yinwei Ho, City of Hope National Medical Center, Duarte, CA; Keh-Dong Shiang, City of Hope National Medical Center, Duarte, CA; David S. Snyder, City of Hope National Medical Center, Duarte, CA; Claudia S. Huettner, Dana-Farber Cancer Institute, Boston, MA; Leonard Shultz, The Jackson Laboratory, Bar Harbor, ME; Tessa Holyoake, University of Glasgow, Scotland, UK; and Ravi Bhatia, City of Hope National Medical Center, Duarte, CA.'
Extrait de http://www.sciencedaily.com/releases/20 ... 132842.htm